NDA 018657 · Baxter Hlthcare
Flagyl I.V. Rtu In Plastic Container
Metronidazole · Injection · Nitroimidazole Antimicrobial
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Dec 24, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
728
132 Phase 3, 52 recruiting
FAERS reports
48,091
0 serious, 5,412 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.
What it is approved for
From the label in effect Nov 21, 2025.
INDICATIONS AND USAGE Treatment of Anaerobic Bacterial Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibacterial drugs appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. • Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis , B. distasonis , B. ovatus , B. thetaiotaomicron , B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species in adults and pediatric patients less than 4 months of age. • Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults. • Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults. • Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults. • Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults. • Central Nervous System (CNS) Infections , including meningitis...
Mechanism: Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 17, 1988 Supplement 7 · Efficacy
- Dec 24, 1981 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- FLAGYL I.V. RTU IN PLASTIC CONTAINER · METRONIDAZOLE 500MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.
- Helicobacter Eradication Aspirin TrialPivotal-lookingCompleted
University of NottinghamAcademic, hospital or other
NCT01506986 · 30,024 participants · Start Mar 2012 · Primary completion Oct 31, 2017
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg · For: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Durham, United Kingdom · 6 sites in all
- The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive TractPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04189744 · 5,436 participants · Start Dec 15, 2019 · Primary completion Oct 21, 2022
Drug: IPTp-sulphadoxine-pyrimethamine plus metronidazole; IPTp-dihydroartemisinin-piperaquine plus metronidazole and 1 more · For: Pregnancy Malaria; Bacterial Vaginoses; Trichomonas Vaginitis
Sites: Nchelenge, Zambia
- Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General PopulationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT02112214 · 5,224 participants (planned) · Start Jun 2014 · Primary completion Dec 2029
Drug: 10-day bismuth-based quadruple therapy · For: Gastric Cancer; Helicobacter Pylori Infection
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 11 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV TransmissionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00021671 · 3,720 participants
Drug: Erythromycin; Nevirapine and 2 more · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- Antibiotic Prophylaxis in Metabolic Bariatric SurgeryPivotal-lookingStatus unknown
General Committee of Teaching Hospitals and Institutes, EgyptGovernment (non-federal)
NCT06510452 · 3,352 participants (planned) · Start Oct 1, 2024 · Primary completion Dec 1, 2025
Drug: 2000 mg of Cefazolin; 500 mg of Metronidazole IV and 1 more · For: Antibiotic Reaction; Wound Infection Superficial; Wound Infection Deep and 2 more
Sites: Alexandria, Egypt; Amersfoort, Netherlands
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.Pivotal-lookingCompleted
Zealand University HospitalAcademic, hospital or other
NCT04803422 · 3,193 participants · Start Apr 1, 2021 · Primary completion May 31, 2024
Drug: Antibiotic · For: Complicated Appendicitis
Sites: Slagelse, Denmark · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,655
- nausea3,458
- off label use3,383
- diarrhoea2,713
- vomiting2,329
- pyrexia2,288
- headache2,258
- abdominal pain2,119
- pain2,119
- fatigue1,959
- dizziness1,684
- condition aggravated1,634
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 459 |
| 2005 | 480 |
| 2006 | 482 |
| 2007 | 511 |
| 2008 | 320 |
| 2009 | 676 |
| 2010 | 858 |
| 2011 | 1,164 |
| 2012 | 1,431 |
| 2013 | 1,112 |
| 2014 | 1,451 |
| 2015 | 2,167 |
| 2016 | 2,469 |
| 2017 | 2,507 |
| 2018 | 4,185 |
| 2019 | 4,489 |
| 2020 | 3,817 |
| 2021 | 3,868 |
| 2022 | 3,400 |
| 2023 | 3,458 |
| 2024 | 3,160 |
| 2025 | 3,437 |
| 2026 | 2,187 |
Recalls
2 FDA enforcement reports for this application.
Jan 21, 2016 · Class I · Terminated
Presence of Particulate Matter: identified as a cloth fiber.
May 21, 2013 · Class II · Terminated
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred...
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical pharmacokinetics of metronidazole: a systematic review and meta-analysis.
Shahzad I, Alasmari MS, Zamir A, et al. · Antimicrob Agents Chemother 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Graber MA, Hollis S, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.
Hong TC, El-Omar EM, Kuo YT, et al. · Lancet Gastroenterol Hepatol 2024 · Meta-Analysis, Systematic Review
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.